China Medical System Holdings Past Earnings Performance
Past criteria checks 2/6
China Medical System Holdings has been growing earnings at an average annual rate of 11%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 11% per year. China Medical System Holdings's return on equity is 15.3%, and it has net margins of 30%.
Key information
11.0%
Earnings growth rate
11.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 11.0% |
| Return on equity | 15.3% |
| Net Margin | 30.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How China Medical System Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 8,013 | 2,401 | 3,168 | 195 |
| 30 Sep 23 | 8,663 | 2,891 | 3,313 | 170 |
| 30 Jun 23 | 9,313 | 3,381 | 3,457 | 146 |
| 31 Mar 23 | 9,232 | 3,320 | 3,408 | 136 |
| 31 Dec 22 | 9,150 | 3,259 | 3,358 | 125 |
| 30 Sep 22 | 9,046 | 3,224 | 3,347 | 129 |
| 30 Jun 22 | 8,942 | 3,189 | 3,336 | 133 |
| 31 Mar 22 | 8,640 | 3,103 | 3,159 | 124 |
| 31 Dec 21 | 8,337 | 3,017 | 2,981 | 115 |
| 30 Sep 21 | 8,009 | 2,948 | 2,782 | 94 |
| 30 Jun 21 | 7,681 | 2,878 | 2,583 | 73 |
| 31 Mar 21 | 7,313 | 2,704 | 2,444 | 70 |
| 31 Dec 20 | 6,946 | 2,530 | 2,304 | 67 |
| 30 Sep 20 | 6,582 | 2,300 | 2,198 | 63 |
| 30 Jun 20 | 6,217 | 2,070 | 2,092 | 60 |
| 31 Mar 20 | 6,145 | 2,015 | 2,119 | 53 |
| 31 Dec 19 | 6,074 | 1,961 | 2,145 | 45 |
| 30 Sep 19 | 5,908 | 2,011 | 2,103 | 30 |
| 30 Jun 19 | 5,743 | 2,062 | 2,060 | 15 |
| 31 Mar 19 | 5,588 | 1,956 | 1,988 | 8 |
| 31 Dec 18 | 5,433 | 1,850 | 1,916 | 0 |
| 30 Sep 18 | 5,375 | 1,839 | 1,829 | 0 |
| 30 Jun 18 | 5,317 | 1,827 | 1,743 | 0 |
| 31 Mar 18 | 5,333 | 1,751 | 1,674 | 0 |
| 31 Dec 17 | 5,349 | 1,675 | 1,604 | 0 |
| 30 Sep 17 | 5,379 | 1,601 | 1,566 | 0 |
| 30 Jun 17 | 5,410 | 1,527 | 1,529 | 0 |
| 31 Mar 17 | 5,155 | 1,452 | 1,462 | 0 |
| 31 Dec 16 | 4,901 | 1,376 | 1,395 | 0 |
| 30 Sep 16 | 4,477 | 1,265 | 1,259 | 0 |
| 30 Jun 16 | 4,054 | 1,155 | 1,123 | 0 |
| 31 Mar 16 | 3,804 | 1,075 | 1,065 | 0 |
| 31 Dec 15 | 3,553 | 996 | 1,007 | 0 |
| 30 Sep 15 | 3,404 | 1,062 | 957 | 0 |
| 30 Jun 15 | 3,255 | 1,128 | 908 | 0 |
| 31 Mar 15 | 3,100 | 1,087 | 845 | 0 |
| 31 Dec 14 | 2,945 | 1,046 | 783 | 0 |
| 30 Sep 14 | 2,760 | 890 | 729 | 0 |
| 30 Jun 14 | 2,575 | 734 | 676 | 0 |
| 31 Mar 14 | 2,412 | 685 | 644 | 0 |
| 31 Dec 13 | 2,249 | 636 | 613 | 0 |
| 30 Sep 13 | 2,081 | 603 | 568 | 0 |
| 30 Jun 13 | 1,961 | 584 | 535 | 0 |
Quality Earnings: 2M7C has high quality earnings.
Growing Profit Margin: 2M7C's current net profit margins (30%) are lower than last year (35.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2M7C's earnings have grown by 11% per year over the past 5 years.
Accelerating Growth: 2M7C's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2M7C had negative earnings growth (-26.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.7%).
Return on Equity
High ROE: 2M7C's Return on Equity (15.3%) is considered low.